DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling

Journal Article · · Cell Systems

We report that clinically used RAF inhibitors are ineffective in RAS mutant tumors because they enhance homo- and heterodimerization of RAF kinases, leading to paradoxical activation of ERK signaling. Overcoming enhanced RAF dimerization and the resulting resistance is a challenge for drug design. Combining multiple inhibitors could be more effective, but it is unclear how the best combinations can be chosen. We built a next-generation mechanistic dynamic model to analyze combinations of structurally different RAF inhibitors, which can efficiently suppress MEK/ERK signaling. This rule-based model of the RAS/ERK pathway integrates thermodynamics and kinetics of drug-protein interactions, structural elements, posttranslational modifications, and cell mutational status as model rules to predict RAF inhibitor combinations for inhibiting ERK activity in oncogenic RAS and/or BRAFV600E backgrounds. Finally, predicted synergistic inhibition of ERK signaling was corroborated by experiments in mutant NRAS, HRAS, and BRAFV600E cells, and inhibition of oncogenic RAS signaling was associated with reduced cell proliferation and colony formation.

Research Organization:
Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
Sponsoring Organization:
USDOE; USDOE Office of Science (SC). Biological and Environmental Research (BER) (SC-23)
Grant/Contract Number:
AC52-06NA25396
OSTI ID:
1564483
Alternate ID(s):
OSTI ID: 1467285
Report Number(s):
LA-UR-18-26812; S2405471218302424; PII: S2405471218302424
Journal Information:
Cell Systems, Journal Name: Cell Systems Vol. 7 Journal Issue: 2; ISSN 2405-4712
Publisher:
ElsevierCopyright Statement
Country of Publication:
Niger
Language:
English
Citation Metrics:
Cited by: 35 works
Citation information provided by
Web of Science

Cited By (6)

Targeting the ERK Signaling Pathway in Melanoma journal March 2019
Targeting the ERK Signaling Pathway in Melanoma journal March 2019
Precision medicine review: rare driver mutations and their biophysical classification journal January 2019
Mapping connections in signaling networks with ambiguous modularity journal May 2019
Prediction of Optimal Drug Schedules for Controlling Autophagy journal February 2019
A patent review of RAF kinase inhibitors (2010–2018) journal August 2019